Trial Profile

The Safety and Efficacy of PD-1 Antibody Combined With Pegylated Interferon-α Therapy to Promote the Clinical Cure in Nucleoside (Acid) Analogues-suppressed Chronic Hepatitis B Patients: A Protocol for the Prospective Pilot Study

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Entecavir (Primary) ; Interferon alpha-2b (Primary) ; Sintilimab (Primary) ; Tenofovir alafenamide (Primary) ; Tenofovir disoproxil fumarate (Primary)
Indications Hepatitis B
Focus Adverse reactions; Therapeutic Use

11 Jun 2024 Planned End Date changed from 30 Oct 2025 to 5 Dec 2025.
11 Jun 2024 Planned primary completion date changed from 30 Oct 2025 to 5 Dec 2025.
07 May 2024 Planned End Date changed from 30 Sep 2025 to 30 Oct 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com